Skip to main content

Glimepiride








Glimepiride


From Wikipedia, the free encyclopedia

Jump to navigation
Jump to search
























































Glimepiride, sold under the trade name Amaryl among others, is medium-to-long-acting sulfonylurea antidiabetic medication. It is taken by mouth. It is sometimes classified as either the first third-generation sulfonylurea,[1] or as second-generation.[2]


In 2016 it was the 61st most prescribed medication in the United States with more than 12 million prescriptions.[3]




Contents





  • 1 Medical uses


  • 2 Contraindications


  • 3 Adverse effects


  • 4 Interactions


  • 5 Pharmacokinetics


  • 6 Mechanism of action


  • 7 References


  • 8 External links




Medical uses[edit]



Glimepiride is indicated to treat type 2 diabetes mellitus; its mode of action is to increase insulin secretion by the pancreas. However it requires adequate insulin synthesis as prerequisite to treat appropriately. It is not used for type 1 diabetes because in type 1 diabetes the pancreas is not able to produce insulin.[4]



Contraindications[edit]


Its use is contraindicated in patients with hypersensitivity to glimepiride or other sulfonylureas.



Adverse effects[edit]


Side effects from taking glimepiride include gastrointestinal tract (GI) disturbances, occasional allergic reactions, and rarely blood production disorders including thrombocytopenia, leukopenia, and hemolytic anemia. In the initial weeks of treatment, the risk of hypoglycemia may be increased. Alcohol consumption and exposure to sunlight should be restricted because they can worsen side effects.[4]



Interactions[edit]


Nonsteroidal anti-inflammatory drugs (such as salicylates), sulfonamides, chloramphenicol, coumadin and probenecid may potentiate the hypoglycemic action of glimepiride. Thiazides, other diuretics, phothiazides, thyroid products, oral contraceptives, and phenytoin tend to produce hyperglycemia.



Pharmacokinetics[edit]




Two generic oral tablets of glimepiride, 2 mg each


Gastrointestinal absorption is complete, with no interference from meals. Significant absorption can occur within one hour, and distribution is throughout the body, 99.5% bound to plasma protein. Metabolism is by oxidative biotransformation, it is hepatic and complete. First, the medication is metabolized to M1 metabolite by CYP2C9. M1 possesses about ​13 of pharmacological activity of glimepiride, yet it is unknown if this results in clinically meaningful effect on blood glucose. M1 is further metabolized to M2 metabolite by cytosolic enzymes. M2 is pharmacologically inactive. Excretion in the urine is about 65%, and the remainder is excreted in the feces.



Mechanism of action[edit]



Like all sulfonylureas, glimepiride acts as an insulin secretagogue.[5] It lowers blood sugar by stimulating the release of insulin by pancreatic beta cells and by inducing increased activity of intracellular insulin receptors.


Not all secondary sufonylureas have the same risk of hypoglycemia. Glibenclamide (glyburide) is associated with an incidence of hypoglycemia of up to 20–30%, compared to as low as 2% to 4% with glimepiride. Glibenclamide also interferes with the normal homeostatic suppression of insulin secretion in reaction to hypoglycemia, whereas glimepiride does not. Also, glibenclamide diminishes glucagon secretion in reaction to hypoglycemia, whereas glimepiride does not.[6]



References[edit]




  1. ^ Hamaguchi T, Hirose T, Asakawa H, et al. (December 2004). "Efficacy of glimepiride in type 2 diabetic patients treated with glibenclamide". Diabetes Res. Clin. Pract. 66 Suppl 1: S129–32. doi:10.1016/j.diabres.2003.12.012. PMID 15563963..mw-parser-output cite.citationfont-style:inherit.mw-parser-output qquotes:"""""""'""'".mw-parser-output code.cs1-codecolor:inherit;background:inherit;border:inherit;padding:inherit.mw-parser-output .cs1-lock-free abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-subscription abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registrationcolor:#555.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration spanborder-bottom:1px dotted;cursor:help.mw-parser-output .cs1-hidden-errordisplay:none;font-size:100%.mw-parser-output .cs1-visible-errorfont-size:100%.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-formatfont-size:95%.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-leftpadding-left:0.2em.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-rightpadding-right:0.2em


  2. ^ Davis SN (2004). "The role of glimepiride in the effective management of Type 2 diabetes". J. Diabetes Complicat. 18 (6): 367–76. doi:10.1016/j.jdiacomp.2004.07.001. PMID 15531188.


  3. ^ "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.


  4. ^ ab "Glimepiride: MedlinePlus Drug Information". nih.gov.


  5. ^ Nissen SE, Nicholls SJ, Wolski K, et al. (April 2008). "Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial". JAMA. 299 (13): 1561–73. doi:10.1001/jama.299.13.1561. PMID 18378631.


  6. ^ Davis, Stephen N. (2005). "60. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas". In Brunton, Laurence L.; Lazo, John S.; Parker, Keith L. (eds.). Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill. p. 1636. ISBN 0-07-142280-3.CS1 maint: Uses editors parameter (link)




External links[edit]


  • http://www.theodora.com/drugs/amaryl_tablets_sanofi_aventis.html

  • http://www.rxlist.com/cgi/generic/glimepiride.htm

Glimepiride
Glimepiride.svg
Clinical data
Trade namesAmaryl, other

AHFS/Drugs.com
Monograph
MedlinePlusa696016
License data


  • EU EMA: by INN

Pregnancy
category


  • US: C (Risk not ruled out)

Routes of
administration
By mouth (tablets)
ATC code

  • A10BB12 (WHO)
Legal status
Legal status


  • US: ℞-only

  • In general: ℞ (Prescription only)



Pharmacokinetic data
Bioavailability100%
Protein binding>99.5%
MetabolismComplete Liver (1st stage through CYP2C9)
Elimination half-life
5–8 hours
ExcretionUrine (~60%), feces (~40%)
Identifiers
CAS Number

  • 93479-97-1 ☑Y

PubChem CID
  • 3476
IUPHAR/BPS
  • 6820
DrugBank

  • DB00222 ☒N
ChemSpider

  • 16740595 ☑Y
UNII
  • 6KY687524K
KEGG

  • D00593 ☑Y
ChEBI

  • CHEBI:5383 ☒N
ChEMBL

  • ChEMBL1481 ☑Y
ECHA InfoCard
100.170.771 Edit this at Wikidata
Chemical and physical data
Formula
C24H34N4O5S
Molar mass490.617 g/mol
3D model (JSmol)
  • Interactive image
Melting point207 °C (405 °F)

.mw-parser-output .noboldfont-weight:normal
 ☒N☑Y (what is this?)
  (verify)














Retrieved from "https://en.wikipedia.org/w/index.php?title=Glimepiride&oldid=875706734"





Navigation menu

























(window.RLQ=window.RLQ||).push(function()mw.config.set("wgPageParseReport":"limitreport":"cputime":"0.872","walltime":"1.079","ppvisitednodes":"value":7281,"limit":1000000,"ppgeneratednodes":"value":0,"limit":1500000,"postexpandincludesize":"value":390015,"limit":2097152,"templateargumentsize":"value":10594,"limit":2097152,"expansiondepth":"value":16,"limit":40,"expensivefunctioncount":"value":2,"limit":500,"unstrip-depth":"value":1,"limit":20,"unstrip-size":"value":18195,"limit":5000000,"entityaccesscount":"value":2,"limit":400,"timingprofile":["100.00% 757.779 1 -total"," 65.53% 496.596 1 Template:Drugbox"," 50.29% 381.089 1 Template:Infobox"," 31.91% 241.802 28 Template:Navbox"," 13.87% 105.070 1 Template:Reflist"," 13.54% 102.571 16 Template:Unbulleted_list"," 9.67% 73.265 3 Template:Cite_journal"," 8.19% 62.030 1 Template:Ion_channel_modulators"," 5.94% 44.996 39 Template:Abbr"," 5.53% 41.917 1 Template:Prostanoidergics"],"scribunto":"limitreport-timeusage":"value":"0.275","limit":"10.000","limitreport-memusage":"value":8599064,"limit":52428800,"cachereport":"origin":"mw1333","timestamp":"20181228132916","ttl":1900800,"transientcontent":false););"@context":"https://schema.org","@type":"Article","name":"Glimepiride","url":"https://en.wikipedia.org/wiki/Glimepiride","sameAs":"http://www.wikidata.org/entity/Q425027","mainEntity":"http://www.wikidata.org/entity/Q425027","author":"@type":"Organization","name":"Contributors to Wikimedia projects","publisher":"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":"@type":"ImageObject","url":"https://www.wikimedia.org/static/images/wmf-hor-googpub.png","datePublished":"2003-06-27T02:36:10Z","dateModified":"2018-12-28T13:29:15Z","image":"https://upload.wikimedia.org/wikipedia/commons/1/17/Glimepiride.svg","headline":"chemical compound"(window.RLQ=window.RLQ||).push(function()mw.config.set("wgBackendResponseTime":107,"wgHostname":"mw1252"););

Popular posts from this blog

The Dalles, Oregon

眉山市

清晰法令